Dissecting the Market Beneficiaries and Sufferers of the 4th Week of May
Advanced stock market trading software has made watching the market easier while trading stocks online. The 4th week of May was bright for some and dull for others in the stock market. So here’s a look at the top beneficiaries and sufferers of the week.
Outlook Therapeutics Inc ($OTLK) secured a Buy rating on TradingView.com on account of its massive 42.35% growth. Avianca Holdings SA ($AVH) soared 28.57% to a value of $3.96 and got a Buy rating.Essa Pharma Inc ($EPIX) climbed 26.83% and was rated a Buy. It reached a value of $2.60. McClatchy Co ($MNI) rose 22.50% to $2.45, but had a Sell rating on TradingView. In the S&P 500, Total System Services Inc ($TSS) rose 13.88% to $113.45. It scored a Buy rating. Intuit Inc ($INTU) soared 6.70% and touched $257.48, and was rated a Strong Buy.
Immuron Limited ($IMRN) sank 29.23% to $3.56 and earned a Sell rating. Therapix Biosciences Ltd ($TRPX) dropped 21% to $2.61. It was rated a Sell. Diffusion Pharmaceuticals Inc ($DFFN) sank 20.32% to $3.80 and secured a Sell rating. In the S&P 500, Foot Locker Inc ($FL) was given a Strong Sell rating after the sportswear retailer stock dipped 16.65% to $44.03 after its earnings missed the estimates of Wall Street. Autodesk Inc ($ADSK) dipped 4.91% to $161.22 and a Sell rating after the 3D printing stock missed sales estimates.
The content provided here is solely for informational and educational purposes and does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by TradeZero in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Investors are advised not to rely on the information contained in this writing to make an informed investment or financial decision. TradeZero explicitly disclaims all liability for any action taken based on any information contained in this writing.